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Abstract 
Annexin A1 is a potent anti-inflammatory molecule that has been extensively studied in the peripheral immune 
system, but has not as yet been exploited as a therapeutic target/agent. In the last decade, we have undertaken the 
study of this molecule in the central nervous system (CNS), focusing particularly on the primary interface between the 
peripheral body and CNS: the blood–brain barrier. In this review, we provide an overview of the role of this molecule 
in the brain, with a particular emphasis on its functions in the endothelium of the blood–brain barrier, and the protec-
tive actions the molecule may exert in neuroinflammatory, neurovascular and metabolic disease. We focus on the 
possible new therapeutic avenues opened up by an increased understanding of the role of annexin A1 in the CNS 
vasculature, and its potential for repairing blood–brain barrier damage in disease and aging.
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Blood–brain barrier structure
The blood–brain barrier (BBB) is the major regulator of 
communication between the peripheral circulation and 
the brain, acting to protect the central nervous system 
(CNS) from the damaging consequences of peripheral 
challenges to homeostasis, such as occur during inflam-
mation and metabolic disease. Given the tight confines 
of the skull, oedema-induced elevated tissue pressure 
is highly damaging to neuronal function [1], hence one 
of the most important functions of the BBB is to limit 
immune cell extravasation, and to protect brain tissue 
from the development of localised inflammation. Simi-
larly, the neural environment is highly metabolically 
active, needing a significant proportion of the body’s 
energy supply [2], and is thus highly vulnerable to meta-
bolic toxins. As a defence against these, another criti-
cal feature of the BBB is the presence of a network of 
highly efficient efflux transporters in cerebral endothelial 
cells, acting to extrude metabolic waste products and to 
prevent potentially toxic molecules from entering the 
brain [3].
The BBB is not an isolated single anatomical structure, 
but is part of the so called neurovascular unit (NVU), a 
morpho-functional unit formed by multiple integrated ele-
ments of the vessel wall (endothelial cells and pericytes), 
encircling perivascular astroglia, microglia cells and inter-
vening neuronal terminals [4] (Fig. 1). Central to the bar-
rier function of the NVU are the endothelial cells. These 
cells are markedly different to other endothelia within the 
body in that they display interendothelial tight junctions 
(TJs) organised in an extensive array of junctional strands; 
a network of close transmembrane protein–protein links 
that, together with adherens junctions and junctional 
adhesion molecules, essentially prevent small molecules 
and invading cells from passing across the vessel wall via 
a paracellular route [5–7]. A number of different proteins 
are involved in forming TJs in the brain vasculature, but 
two of the most important are the molecules occludin and 
claudin-5 which form homodimeric bridges linking neigh-
bouring cells [8]. These molecules in turn complex with a 
series of intracellular elements, including the proteins zona 
occludens-1, -2 and -3 (ZO-1, -2 and -3), which couple to 
the actin cytoskeleton and help give junctions rigidity [9].
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Alongside the paracellular pathway leukocytes migra-
tion occurs also by transcellular pathways which occurs 
in a dynamic interaction between leukocytes protrusions 
at specific site of the endothelium of the BBB [10].
The critical function of the endothelium is the selec-
tive regulation of molecular uptake into the brain paren-
chyma. Given the strength of inter-endothelial TJs, 
small molecule entry into the brain is essentially neg-
ligible under normal conditions. The brain does, how-
ever, require both a significant energy input [2], and the 
removal of neuronal metabolic waste products to the cir-
culation for elimination through the kidneys. As such, an 
array of small molecule transport proteins are expressed 
on the surface of endothelial cells, including transport-
ers for glucose, amino acids, nucleosides and many other 
cations and anions [7, 11]. In addition to these transport-
ers, receptor-mediated uptake systems exist for the larger 
biomolecules such as lipoproteins, peptides and protein 
hormones, permitting the selective entry of molecules 
like insulin and transferrin into the brain. Complement-
ing these uptake systems, the BBB expresses a range of 
highly effective ATP-binding cassette (ABC) family efflux 
transporter systems, most notably P-glycoprotein, breast 
cancer resistance protein (BCRP), multidrug resistance-
associated protein (MRP-1 and MRP-2), which together 
serve to limit exposure of the CNS to potentially neuro-
toxic molecules [12], and which unfortunately are also a 
major barrier to the therapeutic treatment of brain dis-
eases with pharmacological agents [13].
The endothelial cells lie on a complex basal lamina (the 
equivalent of the basement membrane in peripheral ves-
sels without the lamina reticularis) [14], which serves not 
only to provide physical support to the endothelia, but 
also includes pericytes and is a further barrier between 
the circulation and the brain parenchyma [4]. The basal 
lamina is actually a juxtaposed pair of molecular layers 
indistinguishable anatomically at the level of microves-
sels, but originating from endothelial cells and from 
perivascular astrocytes (parenchymal layer). The two 
layers are similarly composed of members of four major 
glycoprotein families: laminins, collagen IV isoforms, 
nidogens and heparin sulphate proteoglycans, including 
VE-Cadherin Zona occludens-1, -2, -3
Occludin Catenins
Claudin-5 F-actin
JAMs
Microglia
Astrocyte end-foot
Pericyte
Endothelial basal 
lamina Endothelium
Lumen
Glia limitans
Fig. 1 Schematic depiction of the principal molecular and cellular components of the neurovascular unit that regulate inter-endothelial permeabil-
ity, and thereby provide the foundation of the blood–brain barrier. JAM junctional adhesion molecule
Page 3 of 15McArthur et al. Fluids Barriers CNS  (2016) 13:17 
perlecan and agrin [15]. They can be distinguished how-
ever, by their complement of laminin subtypes [16], with 
the endothelial basement layer containing laminin-411 
and -511, whilst the parenchymal one contains 
laminin-111 and -211 [17].
The basal lamina is not simply a passive substrate but 
is actively involved in communication across the BBB 
and in the transfer of nutritional support into the brain 
parenchyma [18, 19]. The contribution this molecular 
component of the NVU plays in maintaining BBB integ-
rity has not been fully clarified, but enzymes such as the 
matrix metalloproteinases that disrupt its structure have 
been implicated in inappropriate immune cell or parasite 
entry into the brain [20, 21] and in oedema and haemor-
rhage during cerebrovascular incidents [22–24].
Pericytes embedded in the basal lamina communicate 
with microvessel endothelial cells performing impor-
tant regulatory functions controlling vessel diameter and 
cerebral blood flow [25, 26], and contributing to BBB 
integrity. Mice lacking brain pericytes are embryonically 
lethal, but notably have developing BBBs characterised 
by abnormal distribution of TJ molecules and enhanced 
vascular permeability [27], indicating an important role 
for these cells in either the development, differentiation 
or maintenance of BBB function [28, 29]. This activity is 
confirmed by studies of murine models of reduced cer-
ebral pericyte number, with a strong negative correlation 
existing between brain vessel pericyte coverage and vas-
cular permeability [30], emphasising the importance of 
these cells, even if the fine details of how they contribute 
to BBB integrity remain unclear.
Astrocytes, present on the parenchymal side of the 
vascular basal lamina, are major components of the 
NVU, with individual astrocytes sending out numerous 
processes and endfeet that under pericyte-derived guid-
ance cues, surround and ensheath the vessel wall [30]. 
The astrocyte processes provide considerably more than 
structural support however, as they not only produce 
the molecular components of the parenchymal basal 
lamina limitans [31], but also actively promote TJ for-
mation between endothelial cells [32, 33]. Additionally, 
astrocytes of the BBB have critical roles in brain–blood 
transport; they actively regulate water uptake through 
the major cerebral water channel, aquaporin-4, local-
ized on the plasma membrane of endfeet in contact with 
the vessel wall [34]. They are also intimately involved in 
nutrient uptake [35] and play an important role in the 
removal of neuronal metabolic waste products [36, 37]. 
Whilst less studied than other components of the neuro-
vascular unit, there is some evidence of a role for micro-
glia in the regulation of BBB integrity, particularly under 
inflammatory conditions [38]. Evidence in vitro indicates 
that inflammatory activation of microglia can disrupt 
endothelial TJs through release of reactive oxygen species 
and cytokines [39, 40], but whether this occurs in  vivo, 
and the extent to which microglia influence BBB function 
under normal conditions remains to be investigated.
Together with signalling input from parenchymal 
neurons [41], the neurovascular unit generates a highly 
efficient barrier to free communication between the cir-
culation and the brain, whilst permitting the selective 
uptake of requisite nutrients and water, and enabling 
the removal of waste products of neuronal metabolism. 
Whilst this system is indeed highly effective under nor-
mal homeostatic challenges, it can be significantly per-
turbed following the onset of disease and inflammation.
The blood–brain barrier in inflammation
The BBB is not static, but actively changes and responds 
to inflammatory challenge, whether originating in the 
periphery or the brain parenchyma. Numerous inflam-
matory factors have been shown to enhance BBB perme-
ability, as have recently been reviewed in detail [42–44]. 
Changes to the BBB reflect both alterations in the per-
meability barrier to small molecules and, with particular 
relevance to neurodegenerative conditions such as multi-
ple sclerosis (MS) and Alzheimer’s disease (AD), a loss of 
the normal restrictions on entry of immune cells into the 
brain parenchyma through changes in the expression of 
leukocyte adhesion molecules [45, 46]. The mechanisms 
underlying these changes are complex, and commonly 
involve interacting circuits and feedback loops centred 
on the actions of vasoactive mediators and pro-inflam-
matory cytokines upon endothelial cells and perivascular 
astrocytes [33]. For example, bradykinin not only acts via 
B2 receptors on endothelial cells to open TJs [47], but also 
to induce astrocytic release of interleukin-6, which itself 
can further enhance endothelial cell permeability [48].
On first examination, enhanced BBB permeability upon 
exposure to inflammatory stimulation would appear to 
be maladaptive, but an explanation may lie in consider-
ation of the role the BBB plays in the induction of sick-
ness behaviours. These behaviours, commonly associated 
with inflammatory disease, include deficits in memory 
and attention, lethargy and anhedonia, and are thought 
to provide an adaptive advantage, conserving meta-
bolic energy for the fight against infection/damage [49]. 
Changes in BBB integrity and consequent access of circu-
lating mediators to the CNS parenchyma are thought to 
be one of the major communication pathways underlying 
the induction of these behaviours [50], acting in concert 
with direct vagal information. Although these behaviours 
are advantageous in the short term, helping to promote 
recovery, extended and/or inappropriately severe sick-
ness behaviour can be a major source of morbidity in 
chronic inflammatory conditions [51, 52].
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Evidence for a link between disease-associated 
enhanced BBB permeability and cognitive impairment 
has been steadily accruing, both in age-related cognitive 
decline [51, 53], and in pathologies as diverse as stroke 
[52, 54], vascular dementia [55, 56], AD [57–59], diabetes 
mellitus [60] and obesity [61]. Significantly, many of these 
conditions are associated with peripheral inflammatory 
activity to a greater or lesser extent; hence developing 
an understanding of the factors regulating BBB perme-
ability may offer the opportunity to modify the negative 
cognitive aspects of many inflammatory and neurological 
conditions.
Annexin A1, peripheral inflammation and the BBB
For discussion of the general response of the BBB to 
peripheral and neuroinflammatory challenge we defer 
to recent comprehensive reports [1, 42, 62–64]; in this 
paper we will discuss the specific role of one particular 
mediator known for its peripheral anti-inflammatory/
pro-resolution actions, annexin A1 (ANXA1-Fig. 2), with 
a particular focus on opportunities where it may be used 
therapeutically to restore damaged BBB function.
The role of ANXA1 as a resolving/protecting mol-
ecule in the periphery is well known, as this molecule is 
a secondary mediator of the anti-inflammatory effects 
of glucocorticoid hormones [66], preventing leukocyte 
migration into inflamed tissue [67]. Its role in the CNS 
has been much less comprehensively studied, however. 
ANXA1 belongs to the annexin superfamily of proteins 
(ANXA1–A12) that are near-ubiquitously expressed in 
eukaryotes from mould to mammals (yeasts being the 
only major exception) [68]. ANXA1 is a calcium-depend-
ent phospholipid binding protein with a phospholipase 
A2 inhibitory activity. Structurally ANXA1 presents four 
repeats, three of which contain a Ca2+-binding domain 
(highly conserved among the 13 mammalian annexins) 
and an N-terminal domain with multiple different phos-
phorylation sites that regulate its function [69, 70], and 
which confer its specific anti-inflammatory activity [71]. 
From an evolutionary point of view the structure of the 
ANXA1 gene supports the hypothesis that it arose by 
double duplication of an ancestral single domain gene 
[72]. Interestingly another member of the family ANXA2 
has been recently showed to be involved in miR155 regu-
lation of BBB function [73].
Mechanistically, the auto/paracrine actions of ANXA1 
are transduced by its binding to the G protein-coupled 
receptor formyl peptide receptor 2 (FPR2, also known as 
the lipoxin A4 receptor) [74], which we have shown to be 
expressed on brain microvascular endothelial cells [75], 
and by interaction with membrane phospholipids [76]. 
Numerous intracellular signalling pathways can be acti-
vated downstream of ANXA1 binding to FPR2; activa-
tion of p38 mitogen-activated protein (MAP) kinase [77], 
activation of extracellular signal-regulated protein kinase 
(ERK1/2) and mobilisation of intracellular Ca2+ [78], and 
modification of the actin cytoskeleton through activation 
of small guanosine triphosphate hydrolase (GTPases) [79, 
80] have all been reported.
The role of ANXA1 in the CNS has been debated for 
several years [81], with its central functions only hav-
ing been clarified in the last decade. We and others have 
shown ANXA1 to regulate microglial efferocytosis (non-
inflammatory removal of dead cells), and phagocytosis 
[82–84], supporting a development and anti-inflamma-
tory role, respectively, in the brain. More recently how-
ever, we demonstrated an essential homeostatic function 
of ANXA1, maintaining endothelial TJs in the BBB 
[80], and repairing the permeabilising effect of systemic 
lipopolysaccharides (LPS) on the BBB [64]. We propose 
a dual role for ANXA1 in the CNS vasculature, serving 
as a homeostatic regulator in normal conditions by pro-
moting BBB integrity, and importantly, acting to prevent 
and limit the impact of pathological peripheral challenge 
upon the brain.
Annexin A1 and the regulation of BBB integrity 
across the lifespan
ANXA1 is a critical component of the normal BBB. It is 
expressed by the brain microvascular endothelial cells in 
close proximity to the plasma membrane and at points of 
cell–cell contact where it co-localizes with cortex actin 
microfilaments [75]. Deletion of the ANXA1 gene in 
null mice is associated with disorganization of the actin 
cytoskeleton, reduction of stress fibre formation, cell 
shape changes and a loss of polarity that concludes in the 
disruption of occludin and VE-Cadherin, findings which 
indicate that ANXA1 participates in the regulation of 
Ca++
Ca++
Ca++
2-26 N-terminal domain
Fig. 2 Crystal structure of ANXA1, showing four core Ca2+-binding 
domains, and the N-terminal sequence conferring specificity 
(2–26 N-terminal domain). Adapted from [65]
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BBB permeability through its association with the actin 
cytoskeleton [75]. In normal health conditions, ANXA1 
thus plays a major protective role in the brain through 
the promotion of BBB integrity. There are two stages dur-
ing life, however, when BBB function is less than optimal, 
prenatal development and old age, and there is evidence 
that changes to ANXA1 expression play a role in both.
The BBB was long considered immature and not fully 
functional during development, but there is now consid-
erable evidence that this is not completely true, and that 
many barrier functions are effective from the earliest 
stages of brain ontogeny [85–87]. While this review does 
not focus on the development of the BBB, it is interesting 
to report that we have evidence that ANXA1 is expressed 
by microglia-like cells and BBB endothelial cells during 
human foetal development, further supporting a role 
for the protein in prenatal brain development (Fig.  3). 
ANXA1 mainly localizes to endothelial cell cytoplasm 
and plasma membranes (Fig. 3b) and to a lesser extent to 
the endothelial nucleus (Fig.  3d). It has been suggested 
that in  vitro nuclear translocation of ANXA1 could be 
induced by mitogenic signals [88] and that it could be a 
negative prognostic factor in cancer [66, 67, 89]. How-
ever, the expression of ANXA1 during normal brain 
vascularization and BBB differentiation has not been 
described before and needs to be further investigated.
In contrast, a major feature of aging is a decline in BBB 
integrity [90], with increased paracellular permeability 
and decreased TJ protein expression reported in murine 
models [91]. Intriguingly, human dermal fibroblasts, 
which share a mesenchymal developmental origin with 
endothelial cells, exhibit a profound decrease in ANXA1 
expression with aging [92], leading us to speculate that 
endothelial ANXA1 downregulation may be partially 
responsible for the aged BBB phenotype. This idea is 
supported by the discovery that ANXA1 null mice have 
higher, albeit non-pathological, BBB leakage than age-
matched wild-type controls [64]. Interestingly a protec-
tive role for ANXA1 has been reported in wound healing 
in the gut [93] and bladder epithelia [94], both of which 
are characterised by the presence of intercellular tight 
junctions; structures known to be regulated by ANXA1 
in the BBB [80].
BBB and ANXA1 in human disease
Several studies have indicated a role for ANXA1 in neu-
rological diseases, including Alzheimer’s disease (AD), 
and stroke; although the most compelling evidence is for 
an involvement in the pathology of MS.
Alzheimer’s disease
Alzheimer’s disease is an age-related neurodegenera-
tive disease and the most common form of dementia. 
Pathologically, it is associated with neuronal loss, and 
consequent loss of brain volume that is most pronounced 
around the medial temporal lobe areas, particularly in 
the hippocampus. Histologically, post mortem brains of 
patients present widespread plaques and neurofibril-
lary tangles; important factors in AD pathogenesis. The 
accumulation of amyloid β (Aβ) peptides is believed to 
be a detrimental factor in Alzheimer’s disease progres-
sion, contributing to exacerbated inflammation, micro-
glial activation and neuronal loss. Increased Aβ levels in 
patients’ brains may result from either Aβ overproduc-
tion or inadequate Aβ clearance. Aβ can be cleared via 
the cerebrospinal fluid (CSF) and interstitial fluid (ISF) 
and by enzymatic degradation, but an important route 
for Aβ removal is through efflux transporters present at 
the brain barriers. [95]. Morphological changes at the 
brain barriers that occur in healthy aging are accelerated 
and aggravated in AD. Microvascular reduction and neu-
rovascular dysfunction have been reported in AD [96]. 
Degeneration of pericytes occurs [96, 97] and thickening 
of the basal lamina is more pronounced [98].
Human post mortem studies of AD have reported 
upregulated expression of ANXA1 in lesion-associated 
glia [99, 100] which, given the potent pro-resolution/
anti-inflammatory actions of ANXA1 in the periphery 
[101] may reflect an endogenous attempt to limit cell 
death. This idea is supported by the actions of ANXA1 
in promoting non-phlogistic (non-inflammatory) micro-
glial phagocytosis, even in the face of inflammatory chal-
lenge with Aβ [83], and is further supported by the recent 
identification of a single nucleotide polymorphism in the 
regulatory region of ANXA1 that associates with suscep-
tibility to AD [102].
Increasing evidence indicates that disruption to the 
integrity of the blood–brain barrier is a feature of AD [90, 
103]. Leakage of circulating plasma components into the 
brain parenchyma correlates well with both post mortem 
brain staining of AD [104] and with the rate of cognitive 
decline seen in living AD patients [57, 105]. The impair-
ment of BBB function seen in AD is not restricted to 
plasma leakage, however, AD-related defects have been 
reported in cerebral endothelial efflux transporter activity 
[106, 107] and in abnormal emigration of leukocytes into 
the neuronal tissue [108, 109]. These challenges to BBB 
integrity may have significant consequences for AD pro-
gression, as there is now strong evidence linking enhanced 
BBB permeability with impaired cognitive function, includ-
ing aspects of memory [51], language [52], performance on 
the mini mental state exam [57] and Oxford handicap scale 
[54]. Given the role of ANXA1 in controlling BBB TJ for-
mation and particularly in limiting leukocyte extravasation, 
it is intriguing to speculate on whether the protein plays a 
role in the microvascular endothelial phenotype of AD and 
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whether application of exogenous protein may be able to 
limit disease-associated BBB changes. Although this has 
not been studied directly, raised inflammation and leuko-
cytes trafficking in the peripherally has also reported dur-
ing disease progression [95].
Multiple sclerosis
Multiple sclerosis (MS) is an autoimmune inflamma-
tory disease of the central nervous system associated 
with demyelination and axonal loss, eventually leading 
to neurodegeneration. In general, it affects people under 
50 years old with symptoms usually starting between the 
ages of 20 and 40. It is a disease with a vast clinical and 
pathological heterogeneity, but manifests in three prin-
cipal forms: relapsing remitting (RRMS; the most com-
mon form), primary progressive (PPMS) and secondary 
progressive (SPMS) which tends to be the final stage of 
RRMS. An important factor in the pathogenesis of MS is 
the BBB which is compromised during the course of dis-
ease [110, 111].
A direct link between BBB impairment, ANXA1 
and disease has been indicated in MS, where a clear 
loss of ANXA1 expression has been identified in the 
brain parenchymal capillaries of MS patients, distant 
from lesion sites [80]: a feature which may contrib-
ute to the loss of BBB integrity seen in this condition 
[112]. Importantly, as ANXA1 is also expressed in leu-
kocytes, including both lesional and perivascular mac-
rophages and lymphocytes [113], its role in MS may 
extend beyond the regulation of inter-endothelial TJs, 
to directly modulating the autoimmune side of the dis-
ease. ANXA1 has long been known to inhibit leukocyte 
migration [101] through its interaction with the integ-
rin VLA4 [74], closely resembling the main mechanism 
of action of natalizumab, and highlighting the potential 
of ANXA1 for therapeutic use. ANXA1 may serve as a 
checkpoint between leukocytes and the BBB, on the one 
hand protecting and correcting BBB leakage, and on the 
other directly controlling leukocyte entry into the brain 
parenchyma.
Neurovascular disease and stroke
There is further pre-clinical evidence for a protective/
therapeutic role of ANXA1 in the cerebral vasculature in 
stroke and other neurovascular diseases. Although much 
work has focussed on the role of ANXA1 as a modulator 
of inflammatory microglial activity [81], there is evidence 
for a role in the cerebral vasculature itself. Most notably, 
administration of human recombinant ANXA1 has been 
shown to markedly reduce lesion size, clinical score and 
markers of leukocyte infiltration in murine mid-cerebral 
artery occlusion models of stroke [114]. Animals lacking 
the ANXA1 receptor Fpr2/3 showed markedly greater 
BBB leakage post-ischaemia than their wild-type coun-
terparts [115]. Intriguingly, studies of ischaemic pre-
conditioning regimens, including both chloral hydrate 
anaesthesia [116] and hypothermia [117] indicate that 
these protective treatments act at least in part through 
upregulation of ANXA1.
Given these various clinical and pre-clinical data, we 
would argue that clinical studies of the pharmacokinet-
ics and pharmacodynamics of ANXA1 in healthy sub-
jects are warranted, as a further step towards evaluating 
its potential use in patients with MS and other diseases 
characterised by BBB impairment.
Estrogen, ANXA1 and the BBB in neurovascular disease
An intriguing aspect of the BBB in neurovascular dis-
eases such as stroke lies in the interactions of estrogen 
and ANXA1, and the possible role this protein plays in 
the vasculo-protective action of the hormone. It has long 
been identified that stroke and other neurovascular dis-
eases show marked sex differences in their incidence, with 
males being significantly more commonly affected than 
females [118]. Whilst numerous factors contribute to this 
difference, including rates of metabolic diseases and envi-
ronmental influences, the sex steroid hormone estrogen 
has been shown to be a major discriminating factor [119]. 
The neuroprotective functions of this hormone have been 
extensively studied [118], and it is known that it can exert 
regulatory actions upon immune system function [120], 
but more recent work suggests that estrogen can directly 
target the BBB itself. In particular, estrogen has been 
shown to both protect endothelial cells from cytotoxic 
stimulation and to directly regulate components of the 
BBB, including ANXA1, exerting a positive influence on 
barrier integrity, actions that together help preserve BBB 
function in the face of inflammatory challenge.
(See figure on previous page.) 
Fig. 3 Localisation by immunofluorescence confocal microscopy of ANXA1 in human foetal forebrain at mid-gestation. a, b Single immunolabelling 
for ANXA1 (green) shows a high expression of the protein in microglia-like cells and b in venular, endothelial cells. Note in b the prevalent expres-
sion of ANXA1 on the luminal side of the endothelial plasma membrane (arrow). c, d Double immunolabelling for ANXA1/collagen IV. c The vascular 
basal membrane revealed by collagen IV allow to identify the shows ANXA1 reactivity localised on the endothelial lining; d ANXA1-negative pericyte 
embedded in the basal lamina and the localization of ANXA1 on the endothelial cell nucleus. e, f Double immunolabelling for ANXA1/GFAP shown 
on a confocal single optical plane. e ANXA1 reactıve endothelial cells in contact with GFAP labelled perivascular astrocyte processes; f a detail of 
ANXA1 localization on the endothelial membranes. Nuclear counterstaining with TO-PRO® 3. Bars a, b 10 μm; c 15 μm; d 4 μm; e 25 µm; f 8 µm
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Estrogen is directly protective of cerebral endothelial 
cells following ischaemic damage in  vitro, most notably 
modelled by deprivation and restitution of oxygen and 
glucose (OGD/R). Here, the major circulating estrogen, 
17β-estradiol, was shown to have a potent cytoprotec-
tive action, limiting overt cell death [121], but also act-
ing more directly to prevent hypoxia-inducible factor 1 
α (HIF-1α)-mediated down regulation of the TJ mole-
cules occludin and claudin-5 [122, 123]. These protective 
effects of estradiol on cell viability could be replicated by 
the estrogen receptor α (ERα) agonist propylpyrazoletriol 
(PPT) [121], whilst the actions on TJs were mimicked by 
the ERβ agonist diarylpropionitrile (DPN) [122]. These 
findings highlight an important aspect of the actions of 
estrogen upon the BBB, namely the complexity of recep-
tor-mediated signalling, as brain endothelial cells have 
been shown to express all three major estrogen receptors, 
ERα, ERβ and the G-protein coupled estrogen receptor 
1 (GPER) [124–126]. A major downstream outcome of 
OGD/R damage is the induction of reactive oxygen spe-
cies and, as has been repeatedly shown in studies of the 
neuroprotective potential of estrogen, the hormone is 
able to exert a powerful antioxidant, vasculoprotective 
effect [127]. Estrogen has been shown to protect cerebral 
endothelial cells from both OGD/R-induced [121] and 
iron-mediated oxidative stress [128], although studies 
differ on the relative importance of ERα and ERβ.
Protection against oxidative stress appears to be a 
relatively general effect of estrogen [129], but there is 
evidence that it can additionally exert BBB-specific 
protective actions, most notably through modulation 
of inter-endothelial tight and adherens junction pro-
tein expression. We, and others have shown estradiol to 
upregulate expression of the key TJ molecules claudin-5 
[130], occludin and zona occludens-1 [64, 131], and 
importantly to induce the intracellular relocation of these 
molecules to the cytoplasmic membrane. Whilst estrogen 
appears to directly regulate claudin-5 at a transcriptional 
level [125], the actions of the hormone upon occludin 
and ZO-1 are mediated through ANXA1 [64] following 
activation of ERβ. Fewer studies have been conducted 
upon the effects of estrogen on the BBB in vivo, but it is 
known that male mice show significantly enhanced BBB 
permeability following inflammatory challenge than age-
matched females, a protection lost in ovariectomised ani-
mals and restored by treatment with estradiol [64].
In addition to preventing small molecule entry into the 
brain parenchyma, the BBB is an important check on the 
ability of leukocytes to enter the central nervous system 
[46]. Inflammatory stimulation can activate the cerebral 
endothelium and permit entry of leukocytes into, at the 
least, the perivascular space, primarily through upregu-
lation of cell adhesion molecules such as intercellular 
adhesion molecule 1 (ICAM-1) and vascular cell adhe-
sion molecule 1 (VCAM-1) [132]. Estrogen, again acting 
through ANXA1, can counteract these changes, reducing 
adhesion molecule expression on the luminal surface of 
the endothelium [64, 133], and ultimately preventing leu-
kocyte adhesion and transmigration in the face of inflam-
matory challenge [64]. In this case however, the actions of 
estrogen appear to be mediated by GPER, acting to phos-
phorylate ANXA1 on its N-terminal serine residues [64], 
thereby promoting its secretion and autocrine/paracrine 
feedback [79], ultimately resulting in a down-regulation 
of ICAM-1 expression.
Although not all effects of estrogen upon the BBB 
could be considered protective, e.g. estrogen down-reg-
ulates expression of the major efflux transporter BCRP 
via ERβ [134–136], in general the hormone appears to 
act to counter the damaging impact of peripheral inflam-
mation, protecting the brain from homeostatic challenge. 
Intriguingly, two of the most important of these actions, 
namely the preservation of endothelial TJ integrity and 
the downregulation of inflammatory adhesion molecule 
expression, appear to be mediated through ANXA1, rein-
forcing the role of this protein as a central mediator of 
BBB function.
Metabolic disease and the BBB
Metabolic diseases, such as obesity and diabetes melli-
tus, are major and increasing sources of ill health in the 
human population. These conditions have deleterious 
effects upon virtually every physiological system, and it 
is increasingly apparent that the CNS is not spared in this 
regard. In particular, there is now accumulating evidence 
for a direct impact of metabolic dysregulation upon the 
BBB, representing an important pathway through which 
disorders of metabolism can affect behaviour and cogni-
tion [60, 137].
Several studies have showed obesity to be associated 
with structural brain deficits, including atrophy in the 
frontal lobes, hippocampus, thalamus [138], white [139] 
and grey matter [140], increased BBB permeability [141–
143] and the remodelling of brain microvessels [144], 
suggesting a direct link between dietary habits and BBB 
function. Moreover, obesity has been reported to alter 
neurovascular unit organization, leading to increased 
numbers of perivascular microglia [145] and activation of 
both microglia and astrocytes [145–147]. Interestingly, it 
was reported that even the offspring of obese mice pre-
sented increased BBB permeability at birth, suggesting 
that maternal gestational obesity may be able to compro-
mise BBB formation during development [146].
Furthermore, obesity-induced BBB disruption has been 
associated with down-regulation of cytoskeletal compo-
nent expression in endothelial cells, including vimentin 
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and tubulin [148], and the TJ proteins occludin [142], 
claudin-5 [142, 149] and ZO-1 [148]. As ANXA1 is an 
essential regulator of BBB tightness through stabilisa-
tion of the cytoskeleton [75], we would speculate that its 
expression or post-translational modification might also 
be affected in obesity.
Similarly, experimental studies have also shown that 
obesity is associated with increased neuronal death, BBB 
leakage [141], and infarct volume [144, 150, 151] follow-
ing induction of an ischaemic episode. The deleterious 
effects of obesity in experimental models of stroke may 
be mediated, at least partly, through activation of matrix 
metalloproteinase (MMP)-9, as high fat diet-induced 
obesity increases MMP-9 expression in ischaemic murine 
brain [144, 150] and MMP-9 knockdown reversed the 
damaging effects of obesity following ischaemic challenge 
[144].
Moreover, there are few if any, direct studies of the 
mechanisms underlying the deleterious influence of obe-
sity upon the BBB, but inflammatory pathways may well 
play an important role. It is increasingly evident that 
white adipose tissue secretes a wide variety of biologically 
active adipokines [152], including both pro-inflammatory 
(leptin, tumor necrosis factor α (TNFα) and interleu-
kin 6 (IL-6)) and anti-inflammatory (adiponectin) fac-
tors, which have the potential to regulate endothelial 
function [153], and intriguingly plasma ANXA1 levels 
inversely correlate with indicators of abdominal visceral 
fat [154], suggesting that loss of endothelial ANXA1 may 
also occur in response to chronic obesity-driven inflam-
mation. Obesity has been associated with activation of 
pro-inflammatory pathways in the brain, as a high fat diet 
up-regulated expression of toll like receptor 4 (TLR4), 
high-mobility group protein B1 (HMGB1), vascular 
endothelial growth factor (VEGF) and COX-2 [155]. In 
addition, db/db mice, constitutively showed perivascu-
lar macrophage infiltration [142], exacerbated nuclear 
factor κ B (NFκB) activation [156], and increased IL-1β, 
IL-6, monocyte chemoattractant protein 1 (MCP-1) and 
TNFα release [142]. How and if ANXA1 is involved in 
such pathways remains speculative, but our preliminary 
data suggests that ANXA1 null mice exhibit greater cer-
ebral perivascular CD45+ cell accumulation in response 
to diet-induced obesity than their wild-type counter-
parts, indicating a role for the protein in the regulation of 
immune cell entry into the brain, and further supporting 
our hypothesis that ANXA1 acts to protect BBB integrity. 
Furthermore, the finding that low levels of oxygen inhibit 
the expression of ANXA1 in the pre-adipocytes suggest 
that ANXA1 may have a role in the regulation of inflam-
matory and pro-resolvin pathways necessary to restore 
homeostasis in the inflamed adipose tissue [154].
Diabetes mellitus
A major long-term complication of obesity is diabetes 
mellitus (DM). A growing body of clinical evidence sug-
gests that DM is associated with neuronal dysfunction; 
post mortem human studies indicate that patients with 
DM exhibit reduced brain volume in both grey and white 
matter [157–159] most notably in the hippocampus [157, 
160]. The importance of these findings is emphasised 
in parallel studies indicating DM as a major risk factor 
for dementias including AD [161, 162] and mild cogni-
tive impairment [159, 161], and for stroke [163, 164]. A 
variety of potential mechanisms have been identified 
for these connections, but the role of the BBB has been 
somewhat under-investigated despite accumulating evi-
dence for its involvement in the neuronal component of 
DM. Circulating level of ANXA1 have been reported to 
be downregulated in DM [165], data we have confirmed 
in our high fat diet animal model (ES, unpublished data).
DM-induced BBB disruption is associated with altera-
tions in neurovascular unit organization, with experi-
mental diabetic models exhibiting marked reduction 
in numbers of pericytes [166], but with microglial [167, 
168] and astrocytic activation [168, 169], indicative of 
a local inflammatory response. Additionally, exposure 
of endothelial cells to hyperglycaemia induces a down-
regulation in expression of tight TJ occludin [170–172], 
claudin 5 [149, 170, 172] and ZO-1 [171]. Diabetes mel-
litus (type 1 diabetes-T1DM) has been associated with 
changes in the endothelial basal lamina, further contrib-
uting to disrupted BBB permeability [169].
The alterations in BBB permeability induced by disrup-
tions to glucose homeostasis may be driven, at least in 
part, by increased activity of matrix metalloproteinases 
(MMPs). Studies have shown exacerbation of MMP-2 
activity in serum from patients with T1DM [173], from 
STZ-induced diabetic animals [167, 171] and from 
rat models of diabetes mellitus type 2 (T2DM) [174]. 
Moreover, in vitro studies show that hyperglycaemia can 
increase MMP2 activation [175], whilst BBB disruption 
induced by advanced glycation end-products (AGEs) 
produced under hyperglycaemic conditions can be 
reversed by inhibiting MMP-2 activity [176]. Streptozo-
tocin (STZ)-induced diabetic mice present BBB disrup-
tion associated with exacerbated MMP-9 activity, while 
treatment with S-nitrosoglutathione, a nitric oxide mod-
ulator which is protective against oxidative/nitrosative 
stress, reduces MMP-9 activity and restores normal BBB 
permeability [177]. Intriguingly, ANXA1 has been both 
positively and negatively associated with MMPs expres-
sion in cancer [178–180], and has been shown to be the 
target of AGE-dependent non-enzymatic glycosylation 
in pulmonary endothelial cells in STZ-induced T1DM 
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[181], suggestive of a link between AGE and BBB break-
down in DM.
Beyond the DM-induced alterations of BBB function 
described above, DM has also been associated with CNS 
infiltration of bone marrow-derived macrophages and 
raised levels of pro-inflammatory cytokines in the brain 
parenchyma [167, 169], indicating that the immunologi-
cal barrier functions of the BBB are similarly disrupted by 
DM. Furthermore white matter lesions, lacunar infarcts, 
small strokes, and reductions in cerebral blood flow are 
also reported being induced by DM (type 1 and 2) [182, 
183].Together, these results suggest that DM-induced 
effects on BBB function depends on the interaction 
between several conditions (hyperglycaemia, hypoglycae-
mia, AGEs) inherent to the pathology (Fig. 4). The pos-
sible involvement of ANXA1 in mediating/protecting 
against these changes has not been investigated to date, 
but it is known that human patients with T2DM exhibit 
reduced serum levels of ANXA1 compared with healthy 
control individuals [165]. If this decline is reflected in 
ANXA1 expression in the BBB itself, we can speculate 
that ANXA1 loss would play a major role in transmission 
of inflammatory stimuli into the brain parenchyma, and 
the associated cognitive disturbances seen in DM [60] 
(Fig. 4).
Conclusion
The BBB as a critical communication interface between 
the brain and the rest of the body has long been known 
to play a role in neurological disease, but it is increasingly 
realised that dysfunction is a feature of other homeostatic 
disorders, most notably metabolic diseases such as obesity 
and diabetes mellitus. A loss of BBB integrity is thought to 
directly contribute to the cognitive, behavioural and neuro-
logical symptoms of these conditions, which to date have 
received scant attention in either research or medical prac-
tice. Strategies to reverse BBB damage may therefore be of 
great utility in addressing the neurological symptoms of 
many clinical conditions. In this review, we propose that 
therapeutic use of a major regulator of BBB integrity and 
Fig. 4 Schematic representation of possible mechanisms linking metabolic disorders, BBB dysfunction and neurodegeneration. Metabolic imbal-
ance associated with obesity and DM leads to chronic systemic, low-grade inflammation and the down-regulation of circulating ANXA1. Interaction 
of circulating soluble factors with brain endothelial cells induces tight junction disruption and BBB leakage, permitting leukocyte migration and 
glial activation, which in turn can impair neuronal function through production of pro-inflammatory mediators and reactive oxygen species (AGEs 
advanced glycation end-products; ROS reactive oxygen species)
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function, ANXA1, may serve as such a strategy. Several 
alternative approaches to the therapeutic use of ANXA1 
are currently under development. One aims to avoid the 
inherent problems of using a full-length protein in the 
clinic; namely the administration of N-terminal ANXA1 
peptides [115, 184]. Unfortunately these efforts are some-
what limited by the propensity of these agents to signal 
through both FPR2 and the pro-inflammatory receptor 
FPR1 [185]. More promising might be through the delivery 
of microvesicle-encapsulated proteins. This latter approach 
has been shown to be potently anti-inflammatory in animal 
models of rheumatoid arthritis [186], colitis [93] and ath-
erosclerosis [187]. Hence it could prove to be valuable in 
the treatment of conditions characterised by damaged BBB 
integrity, including such major disorders as Alzheimer’s 
disease, multiple sclerosis and diabetes mellitus. Delivery of 
ANXA1 thus holds great potential as a way to reverse BBB 
damage induced by inflammation or metabolic challenge, 
and in doing so restore normal BBB function.
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